You are here
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial
Journal of the Neurological Sciences, June 2016, Pages 190 - 198
Depression is common in patients with multiple sclerosis (MS), may confound evaluation of therapeutic effectiveness and may be impacted by MS-specific treatments.
First, to assess the impact on depressive symptoms of a switch to fingolimod versus remaining on an injectable disease-modifying therapy (iDMT) in a post-hoc analysis of prospectively collected data from the EPOC study. Secondly, to investigate the underlying Beck Depression Inventory-II (BDI-II) factor structure in patients with MS, and estimate treatment differences using the resulting subscales.
EPOC was a 6-month, open-label study assessing patient-reported outcomes after switch from iDMT to oral fingolimod 0.5 mg versus remaining on iDMT in 1053 patients with relapsing–remitting MS.
At end of study (EOS), a greater proportion of patients on fingolimod versus iDMT no longer had BDI-II scores indicating depression (p < 0.001). Fewer mildly and moderately symptomatic patients developed severe depressive symptoms, and fewer severely symptomatic patients continued to have scores indicating severe depression at EOS on fingolimod versus iDMT (p = 0.027, p = 0.038, p = 0.030, respectively). Two BDI-II subscales were identified and labelled Somatic and Affective; fingolimod demonstrated more reduction on both subscales at EOS versus iDMTs (p < 0.0001 and p = 0.0001, respectively).
A switch to fingolimod versus remaining on/switching to another iDMT was associated with an improvement in depressive symptoms in patients with relapsing–remitting MS.
- Multiple sclerosis (MS)-specific treatments may cause or exacerbate depression.
- Switching therapies may therefore impact on depression in relapsing-remitting MS.
- Injectable disease-modifying treatments (iDMT) and oral fingolimod were compared.
- Depressive symptoms improved after switch to fingolimod vs switch to/stay on iDMT.
Keywords: BDI-II, Depression, Fingolimod, Multiple sclerosis, Patient-reported outcomes, Satisfaction.
a Advanced Neurosciences Institute, 101 Forrest Crossing Blvd, Suite 103, Franklin, TN 37064, USA
b Neurology Department, Barrow Neurological Institute, Phoenix AZ 85013, USA
c The Mellen Center, Cleveland Clinic Foundation, 1950 East 89th Street, Cleveland, OH 44195, USA
d University of Alabama at Birmingham, 1400 University Boulevard, Birmingham, AL 35223, USA
e Novartis Pharmaceuticals Corporation, 1 Health Plz, East Hanover, NJ 07936, USA
f Albert Einstein College of Medicine and Montefiore Medical Center, 111 East 210th Street, Bronx, New York, NY 10467, USA
⁎ Corresponding author.
1 With the exception of one patient found subsequently to be ineligible for inclusion according to the study protocol.
© 2016 Elsevier B.V., All rights reserved.